随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
63-летняя Деми Мур вышла в свет с неожиданной стрижкой17:54，详情可参考safew官方下载
。业内人士推荐旺商聊官方下载作为进阶阅读
set pixel as closest colour to offset
Lex: FT’s flagship investment column。业内人士推荐搜狗输入法下载作为进阶阅读
Last October the investment bank Goldman Sachs put out a report, which was widely cited, suggesting the US could be facing a new period of "jobless growth" thanks to the arrival of new technology and artificial intelligence (AI) in particular, allowing companies to do more with fewer workers.